Drug Trial Radar · NCT05432804
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
97
Planned (sponsor's estimate)
Start
Mar 20, 2023
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.
Conditions
- Recurrent Glioblastoma, IDH-Wildtype
- Recurrent MGMT-Methylated Glioblastoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Magnetic Resonance ImagingProcedure
Undergo MRI
Placebo AdministrationDrug
Given PO
SelinexorDrug
Given PO
TemozolomideDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase 2 dose (RP2D) (Phase I)Time frame: Up to 28 days
- Progression-free survival (PFS) (Phase II)Time frame: From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Keck Medicine of USC Koreatown
Los Angeles, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Doral
Doral, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Cooperman Barnabas Medical Center
Livingston, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Rutgers New Jersey Medical School
Newark, New Jersey · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Active not recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Montefiore Medical Center-Einstein Campus
The Bronx, New York · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah · Suspended
University of Virginia Cancer Center
Charlottesville, Virginia · Active not recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Active not recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin · Recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.